Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Skin Pharmacol Physiol ; 29(6): 324-331, 2016.
Article in English | MEDLINE | ID: mdl-28099963

ABSTRACT

Low-molecular-weight antioxidants are some of the most efficient agents of the skin defense mechanism against environmental factors, such as cosmic rays, smoke, and pollutants. The total skin concentrations of hydrophilic ascorbic and uric acids, as well as lipophilic α-tocopherol, ß-carotene, and ubiquinol-10 antioxidants were determined by an HPLC-EC detector from 18 biopsies of human nonmelanoma skin carcinomas and 18 biopsies from skin areas adjacent to carcinomas. No significant differences in the concentrations of lipophilic antioxidants in both carcinomas and normal-looking skin areas adjacent to carcinomas were observed. On the contrary, ascorbic and uric acid concentrations were found to be 18 and 36% lower in carcinomas than in normal-looking skin areas, respectively. No statistical significance was observed between antioxidant concentrations and age, sex, phototype, profession, site of tumor, frequency, and time of UV light exposure either. Accordingly the antioxidant concentrations in both cancerous skin and adjacent normal-looking areas were found to be much higher than in normal skin, in contrast to literature data.


Subject(s)
Ascorbic Acid/metabolism , Skin Neoplasms/metabolism , Skin/metabolism , Ubiquinone/analogs & derivatives , Uric Acid/metabolism , alpha-Tocopherol/metabolism , beta Carotene/metabolism , Adult , Aged , Aged, 80 and over , Antioxidants/chemistry , Antioxidants/metabolism , Ascorbic Acid/chemistry , Carcinoma, Basal Cell/metabolism , Carcinoma, Squamous Cell/metabolism , Female , Humans , Male , Middle Aged , Molecular Weight , Ubiquinone/chemistry , Ubiquinone/metabolism , Uric Acid/chemistry , alpha-Tocopherol/chemistry , beta Carotene/chemistry
2.
Acta Derm Venereol ; 89(2): 134-9, 2009.
Article in English | MEDLINE | ID: mdl-19325996

ABSTRACT

The aim of this study was to determine whether imiquimod, a Toll-like receptor-7/8 agonist, in addition to its well-known topical action on the cutaneous immune response, might also induce alterations in the peripheral blood lymphocytes. A 62.5 mg quantity of imiquimod (5% cream) was applied topically under occlusion once daily every second day for 3 weeks to the skin of 10 healthy volunteers, age range 30-57 years. Ten sex- and age-matched healthy controls applied corresponding quantities of the vehicle under occlusion. Before, and one and 3 weeks after the start of treatment, peripheral blood lymphocyte subpopulations were measured by flow cytometry. Statistically significant alterations in the percentage or absolute numbers of peripheral blood lymphocyte subpopulations were found in the imiquimod-treated group compared with the control group. These alterations indicate for the first time that topical application of imiquimod induces alterations in peripheral blood lymphocyte subsets in healthy individuals, which may be of importance in the immunotherapy of neoplastic and infectious disorders and should be taken into careful consideration in patients who are treated with imiquimod.


Subject(s)
Adjuvants, Immunologic/pharmacology , Aminoquinolines/pharmacology , Lymphocytes/drug effects , Adjuvants, Immunologic/administration & dosage , Administration, Cutaneous , Adult , Aminoquinolines/administration & dosage , Antigens, CD/analysis , HLA-DR Antigens/analysis , Humans , Imiquimod , Lymphocyte Subsets/drug effects , Lymphocytes/immunology , Male , Middle Aged , Toll-Like Receptor 7/agonists , Toll-Like Receptor 8/agonists
3.
Acta Derm Venereol ; 85(5): 389-93, 2005.
Article in English | MEDLINE | ID: mdl-16159728

ABSTRACT

Heat shock protein 27 (Hsp27), apart from its protective function in response to stress, is implicated in the regulation of cell growth, differentiation and apoptosis. Data on the expression of Hsp27 in the developing human epidermis are sparse and partially conflicting. Thus, the purpose of the present study was to investigate Hsp27 expression during the morphogenesis of human epidermis. Skin biopsies and dispase-separated epidermal sheets obtained from 7 human embryos (7 and 8 weeks estimated gestational age, EGA), from 79 human fetuses (9-23 weeks EGA) and from 10 healthy adult volunteers were investigated by immunohistochemistry and Western blotting, respectively. The earliest detection of Hsp27 expression was found by immunohistochemistry at the 12th week EGA (basal and intermediate layer) and by Western blotting at the 9th week EGA. From the 16th to the 23rd week EGA immunoreactivity was not detectable in the basal layer, whereas in the overlying layers it revealed a differentiation-related pattern. The simultaneous onset of epidermal stratification and Hsp27 expression (9th week EGA) and the alterations of the latter in the subsequent stages of development, suggest that this stress protein may be involved in the molecular events underlying human epidermal morphogenesis.


Subject(s)
Epidermis/embryology , Epidermis/metabolism , Heat-Shock Proteins/metabolism , Adult , Blotting, Western , Gestational Age , Humans , Immunohistochemistry , Morphogenesis
4.
Int J Radiat Oncol Biol Phys ; 57(2): 402-8, 2003 Oct 01.
Article in English | MEDLINE | ID: mdl-12957251

ABSTRACT

PURPOSE: Radiochemotherapy (RCT) is an effective treatment for locally advanced non-small-cell lung cancer (NSCLC), but can be limited by acute and late toxicities (esophagitis, pneumonitis, and myelosuppression). This trial investigated whether pretreatment with amifostine, a radioprotector, could reduce the incidence of radiochemotherapy-induced acute and late toxicities. METHODS AND MATERIALS: Between October 1997 and August 1999, 73 patients with previously untreated Stage IIIa-IIIb NSCLC were randomized to treatment with RCT alone (n = 36) or RCT plus amifostine (300 mg/m(2) daily i.v. infusion, n = 37). RCT consisted of either paclitaxel (60 mg/m(2)) or carboplatin (AUC 2) once weekly during a 5- to 6-week course of conventional radiotherapy given as 2 Gy/5 days/week to a total dose of 55 to 60 Gy. Blood cell counts were measured weekly; esophagitis and acute lung toxicity were evaluated during the treatment course. Treatment efficacy was assessed following World Health Organization criteria for response. Late lung toxicity was assessed at 3 and 6 months after RCT and was graded from 0 to 4 according to the Radiation Therapy Oncology Group/European Organization for the Research and Treatment of Cancer criteria. RESULTS: A total of 68 patients were evaluable for toxicity analysis (RCT group, n = 32; RCT + amifostine, n = 36). There was no significant difference between treatment arms in patient baseline characteristics. The incidence of Grade >or=3 esophagitis during RCT was significantly lower for patients receiving amifostine than for patients receiving RCT alone (38.9% vs. 84.4%%, p < 0.001). Furthermore, the incidence of Grade >or=3 acute pulmonary toxicity was significantly reduced in patients treated with RCT plus amifostine compared to patients who received RCT alone (19.4% vs. 56.3%, p = 0.002). At 3 months after RCT, patients treated with amifostine had a significantly lower incidence of pneumonitis than patients who received RCT alone (p = 0.009). Combined response rates (complete plus partial responses) were 82.2% in the RCT group and 88.8% in the RCT plus amifostine group (p = 0.498). Amifostine is effective in reducing the incidence of both acute and late toxicities associated with RCT in patients with locally advanced NSCLC without compromising antitumor efficacy.


Subject(s)
Amifostine/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma, Non-Small-Cell Lung/drug therapy , Carcinoma, Non-Small-Cell Lung/radiotherapy , Lung Neoplasms/drug therapy , Lung Neoplasms/radiotherapy , Radiation Injuries/prevention & control , Radiation-Protective Agents/therapeutic use , Carboplatin/administration & dosage , Combined Modality Therapy , Esophagitis/etiology , Esophagitis/prevention & control , Female , Humans , Male , Middle Aged , Mouth Mucosa/radiation effects , Paclitaxel/administration & dosage , Radiation Pneumonitis/prevention & control , Radiotherapy Dosage , Stomatitis/etiology , Stomatitis/prevention & control , Treatment Outcome
5.
Semin Oncol ; 30(6 Suppl 18): 2-9, 2003 Dec.
Article in English | MEDLINE | ID: mdl-14727235

ABSTRACT

Radiochemotherapy (RCT) is an effective treatment for locally advanced non-small cell lung cancer, but can be limited by acute and late toxicities (esophagitis, pneumonitis, and myelosuppression). This trial investigated whether pretreatment with amifostine (Ethyol, WR-2721; MedImmune, Inc, Gaithersburg, MD), a radioprotector, could reduce the incidence of RCT-induced acute and late toxicities. Between October 1997 and August 1999, 73 patients with previously untreated stage IIIa-IIIb non-small cell lung cancer were randomized to treatment with RCT alone or RCT plus amifostine (300 mg/m(2) daily intravenous infusion). Chemotherapy consisted of either paclitaxel (60 mg/m(2)) or carboplatin (area under the concentration-curve of 2) once weekly during a 5- to 6-week course of conventional radiotherapy given as 2 Gy daily fraction, 5 days a week to a total dose of 55 to 60 Gy. Esophagitis and acute lung toxicity were evaluated during treatment; late lung toxicity was assessed at 3 and 6 months after RCT and was graded from 0 to 4 according to the Radiation Therapy Oncology Group/European Organization for the Research and Treatment of Cancer criteria. Esophageal endoscopy was performed the fourth week during RCT and 1 month after the end of RCT. Endoscopic findings of radiation esophagitis were scored from 0 to 3. There was no significant difference between treatment arms in baseline patient characteristics. A total of 68 patients were evaluable for toxicity and efficacy (RCT group, n = 32; RCT plus amifostine, n = 36). The incidence of grade >or= 3 esophagitis during RCT was significantly lower for patients receiving amifostine than for those receiving RCT alone (38.9% v 84.4%; P <.001). The incidence of grade >or= 3 acute pulmonary toxicity was also significantly reduced in amifostine-treated patients (19.4% v 56.3%; P =.002). At 3 months following RCT, patients treated with amifostine had a significantly lower incidence of pneumonitis than those who received RCT alone (P =.009). Endoscopic grade >or= 2 esophagitis was observed in eight of 15 patients in the RCT group and in three of 18 patients in the RCT plus amifostine group (P =.061). No significant differences in response rates were noted between patients receiving RCT with or without amifostine (P =.498). Amifostine is effective in reducing the incidence of both acute and late toxicities associated with RCT in patients with locally advanced non-small cell lung cancer without compromising antitumor efficacy.


Subject(s)
Amifostine/therapeutic use , Antineoplastic Agents/adverse effects , Carcinoma, Non-Small-Cell Lung/drug therapy , Carcinoma, Non-Small-Cell Lung/radiotherapy , Esophagitis/prevention & control , Lung Neoplasms/drug therapy , Lung Neoplasms/radiotherapy , Radiation Injuries/prevention & control , Radiation-Protective Agents/therapeutic use , Radiation-Sensitizing Agents/adverse effects , Aged , Antineoplastic Agents/therapeutic use , Carboplatin/adverse effects , Carboplatin/therapeutic use , Combined Modality Therapy/adverse effects , Esophagitis/etiology , Female , Humans , Male , Middle Aged , Paclitaxel/adverse effects , Paclitaxel/therapeutic use , Radiation Pneumonitis/prevention & control , Radiation-Sensitizing Agents/therapeutic use
6.
Leuk Res ; 26(2): 143-54, 2002 Feb.
Article in English | MEDLINE | ID: mdl-11755464

ABSTRACT

The multidrug resistance (MDR) transporter-proteins P-glycoprotein (Pgp), multidrug resistance protein (MRP) and lung resistance protein (LRP) have been associated with treatment failure. The aim of this study was to investigate prospectively the clinical significance of expression and function of the MDR proteins, considering other prognostic factors, such as age, immunophenotype, and cytogenetics. Mononuclear cells of peripheral blood or bone marrow from 61 patients with de novo acute myelogenous leukemia (AML) were analyzed. The monoclonal antibodies JSB1, MRPm6 and LRP56 were used for expression studies. Accumulation and retention studies were performed using the substrates Daunorubicin, Calcein-AM, Rhodamine-123 and DiOC(2) in the presence or absence of the modifiers Verapamil, Genistein, Probenecid, BIBW22S and PSC833. Induction treatment consisted of a 3+7 combination of Ida/Ara-C for patients < or = 60 years of age and a 3+5 Ida/VP-16 combination per OS for patients >60. MDR function was expressed as the ratio of mean fluorescence intensity substrate in the presence of modifier over the substrate alone (resistance index, RI). Patients with advanced age, low CD15 expression and high RI for accumulation of DiOC(2) in the presence of BIBW22S had significantly lower complete remission (CR) rates. No factor was prognostic for event-free survival analysis, which was limited to remitters only. Overall survival was shorter in patients with advanced age, poor prognosis cytogenetics, high CD7 expression, and high RI for Daunorubicin efflux modulated by Verapamil. These results suggest that MDR transporter-proteins have a limited role in the treatment failure of patients treated with Idarubicin-based regimens.


Subject(s)
ATP Binding Cassette Transporter, Subfamily B, Member 1/physiology , Drug Resistance, Multiple/genetics , Drug Resistance, Neoplasm/genetics , Leukemia, Myeloid/metabolism , Multidrug Resistance-Associated Proteins/physiology , Neoplasm Proteins/physiology , Vault Ribonucleoprotein Particles/physiology , ATP Binding Cassette Transporter, Subfamily B, Member 1/biosynthesis , ATP Binding Cassette Transporter, Subfamily B, Member 1/genetics , Acute Disease , Adolescent , Adult , Age Factors , Aged , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Bone Marrow Transplantation , Calcium Channel Blockers/pharmacology , Carbocyanines/metabolism , Combined Modality Therapy , Cytarabine/administration & dosage , Daunorubicin/metabolism , Disease-Free Survival , Enzyme Inhibitors/pharmacology , Female , Fluoresceins/metabolism , Fluorescent Dyes/metabolism , Genistein/pharmacology , Humans , Idarubicin/administration & dosage , Immunophenotyping , Leukemia, Myeloid/drug therapy , Leukemia, Myeloid/genetics , Leukemia, Myeloid/mortality , Leukemia, Myeloid/therapy , Male , Middle Aged , Multidrug Resistance-Associated Proteins/biosynthesis , Multidrug Resistance-Associated Proteins/genetics , Neoplasm Proteins/biosynthesis , Neoplasm Proteins/genetics , Probenecid/pharmacology , Prognosis , Prospective Studies , Rhodamine 123/metabolism , Survival Analysis , Tumor Cells, Cultured/metabolism , Vault Ribonucleoprotein Particles/biosynthesis , Vault Ribonucleoprotein Particles/genetics , Verapamil/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...